阿托伐他汀联合非诺贝特治疗混合型高脂血症的疗效和安全性分析

Curative effect and safety of atorvastatin combining fenofibrate in treatment of mixed hyperlipidemia

目的：分析阿托伐他汀联合非诺贝特治疗混合型高脂血症的疗效和安全性。方法选取北京市西城区广内医院自2010年6月至2013年6月收治的混合型高脂血症老年患者120例，男性68例，女性52例，年龄60~82岁，平均（67.2±5.9）岁。根据入院先后顺序随机分为研究组和对照组，每组60例。对照组口服阿托伐他汀钙20 mg，研究组在对照组的基础上服用非诺贝特胶囊200 mg，连续治疗12周。比较两组患者总胆固醇（TC）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）及三酰甘油（TG）水平以及不良反应情况。结果研究组显效27例，有效30例，总有效率95.0%，显著高于对照组83.3%，差异有统计学意义（P＜0.05）。与对照组比较，研究组治疗6周后TG、TC、LDL-C下降， HDL-C升高，差异有统计学意义（P均＜0.05）。研究组治疗12周后较对照组TG、TC、LDL-C下降， HDL-C升高，差异有显著统计学意义（P均＜0.01）。两组总不良反应发生率比较（8.3%vs.6.7%），差异无统计学意义（P＞0.05）。结论阿托伐他汀联用非诺贝特对于混合型高脂血症患者具有较好的临床疗效，值得临床推广。

Objective To analyze the curative effect and safety of atorvastatin combining fenofibrate in treatment of mixed hyperlipidemia. Methods The elderly patients with mixed hyperlipidemia （n=120, male 68, female 52, aged from 60 to 82 and average age=67.2±5.9） were chosen from June 2010 to June 2013, and then divided randomly into study group and control group （each n=60）. The control group and study group were given atorvastatin （20 mg） and study group was additionally given fenofibrate （200 mg） for 12 w. The levels of total cholesterol （TC）, high-density lipoprotein-cholesterol （HDL-C）, low-density lipoprotein-cholesterol （LDL-C） and triglyceride （TG）, and adverse reactions were observed and compared in 2 groups. Results There were 27 patients with significant efficacy and 30 with efficacy, and the total effective rate was 95.0%in study group, which was higher than that in control group （83.3%, P0.05） between 2 groups. Conclusion Atorvastatin combining fenofibrate has higher clinical efficacy in patients with mixed hyperlipidemia, which is worthy of clinic application.